"Skip to content\nHome\nProducts\nClinical\nNews\nInvestors\nAbout Us\nContact Us\nINVEST NOW\nNEWS\nHeartSciences Bets Big on AI Amid Surging Heart Disease Deaths\nApril 15, 2024\nFor HeartSciences CEO Andrew Simpson, the pandemic’s fallout only underscores the urgent need for better cardiac diagnostic tools.\n\nHeartSciences Bets Big on AI Amid Surging Heart Disease Deaths\n\nIn a bold move that could reshape the fight against America’s top killer, medical technology startup HeartSciences is going all-in on artificial intelligence. The company recently announced that it’s shifting its focus from a single AI-enabled device to a comprehensive cloud-based platform, a pivot accompanied by a major licensing deal with Mount Sinai for a suite of cutting-edge AI algorithms.\n\nThe strategic gambit comes as new CDC data reveals the devastating toll the COVID-19 pandemic has taken on the nation’s cardiovascular health. In the three years since the virus first upended daily life, the U.S. has seen a staggering 228,000 more cardiac deaths than expected, a grim reversal of long-term progress against heart disease.\n\nFor HeartSciences CEO Andrew Simpson, the pandemic’s fallout only underscores the urgent need for better cardiac diagnostic tools. The company’s new cloud-based approach is all about democratizing access to advanced diagnostics. By making its AI tools compatible with the ECG devices already ubiquitous in clinics and hospitals, HeartSciences hopes to dramatically expand its reach and impact.\n\nValidation studies suggest the startup’s algorithms can indeed flag cardiac abnormalities that standard screening tests frequently miss, especially in populations like diabetics who face elevated risk.\n\nNavigating the FDA clearance process will be critical for HeartSciences. Still, with heart disease mortality on a troubling upswing and the pandemic’s ripple effects far from over, the status quo is increasingly untenable. For companies like HeartSciences, the race is on to prove that AI’s promise in cardiac care is more than just hype – and to ensure that its benefits reach those most in need.\n\nAs the startup charges ahead with its cloud pivot and Mount Sinai partnership, all eyes will be on its progress. In a healthcare landscape reshaped by COVID-19, the stakes for innovation have never been higher. For the millions of Americans at risk of dying from a broken heart, the hope is that AI might finally start to heal.\n\nDisclaimer: This article is a paid publication and does not have journalistic/editorial involvement of Hindustan Times. Hindustan Times does not endorse/subscribe to the content(s) of the article/advertisement and/or view(s) expressed herein. Hindustan Times shall not in any manner, be responsible and/or liable in any manner whatsoever for all that is stated in the article and/or also with regard to the view(s), opinion(s), announcement(s), declaration(s), affirmation(s) etc., stated/featured in the same.\n\nLink to article: HeartSciences Bets Big on AI Amid Surging Heart Disease Deaths | Mint (livemint.com)\n\nContacts\nMEDIA RELATIONS\n\nGene Gephart\nDirector of Marketing\n+1-682-244-2578 (US)\n\ngene.gephart@heartsciences.com\nINVESTOR CONTACT\n\nMark Komonoski – Partner\nIntegrous Communications\nDirect: 877-255-8483\n\ninvestorrelations@heartsciences.com\nwww.integcom.us\n